ATE186840T1 - Zusammensetzungen und methoden zur wundbehandlung - Google Patents

Zusammensetzungen und methoden zur wundbehandlung

Info

Publication number
ATE186840T1
ATE186840T1 AT92919722T AT92919722T ATE186840T1 AT E186840 T1 ATE186840 T1 AT E186840T1 AT 92919722 T AT92919722 T AT 92919722T AT 92919722 T AT92919722 T AT 92919722T AT E186840 T1 ATE186840 T1 AT E186840T1
Authority
AT
Austria
Prior art keywords
formulations
methods
compositions
wound treatment
effective amount
Prior art date
Application number
AT92919722T
Other languages
English (en)
Inventor
Ella Lindenbaum
Original Assignee
Technion Res & Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technion Res & Dev Foundation filed Critical Technion Res & Dev Foundation
Application granted granted Critical
Publication of ATE186840T1 publication Critical patent/ATE186840T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028—Polypeptides; Proteins; Degradation products thereof
    • A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Physical Water Treatments (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT92919722T 1991-08-30 1992-08-28 Zusammensetzungen und methoden zur wundbehandlung ATE186840T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75284991A 1991-08-30 1991-08-30

Publications (1)

Publication Number Publication Date
ATE186840T1 true ATE186840T1 (de) 1999-12-15

Family

ID=25028127

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92919722T ATE186840T1 (de) 1991-08-30 1992-08-28 Zusammensetzungen und methoden zur wundbehandlung

Country Status (12)

Country Link
US (1) US5461030A (de)
EP (1) EP0650366B1 (de)
JP (1) JPH06510453A (de)
AT (1) ATE186840T1 (de)
AU (1) AU670413B2 (de)
BR (1) BR9206433A (de)
CA (1) CA2116549A1 (de)
DE (1) DE69230344T2 (de)
FI (1) FI940932A0 (de)
HU (1) HUT67319A (de)
IL (1) IL101229A0 (de)
WO (1) WO1993004691A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705485A (en) * 1987-09-18 1998-01-06 Ethicon, Inc. Gel formulations containing growth factors
US5591709A (en) * 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
US20020091155A1 (en) * 1995-06-22 2002-07-11 Btg Pharmaceutical Corp. Method for ameliorating muscle weakness/wasting in a patient infected with human immunodeficiency virus-type 1
US5840770A (en) * 1993-08-24 1998-11-24 Hill Medical Corporation Method of killing tumor cells
US5449522A (en) * 1993-08-24 1995-09-12 Hill; Albert F. Pharmaceutical composition for immunoenhancement therapy
AUPM678294A0 (en) * 1994-07-13 1994-08-04 Gropep Pty Ltd Use of insulin-like growth factor in combination with insulin
US6821780B2 (en) * 1995-01-09 2004-11-23 Jean-Noel Thorel Complete nutrient medium for use as a cosmetic and cosmetic use thereof
US6380255B1 (en) * 1995-06-07 2002-04-30 Karo Bio Ab Treatment for dermal skin atrophy using thyroid hormone compounds or thyroid hormone-like compounds
US5681561A (en) * 1995-06-07 1997-10-28 Life Medical Sciences, Inc. Compositions and methods for improving autologous fat grafting
ES2293137T3 (es) 1995-10-11 2008-03-16 Novartis Vaccines And Diagnostics, Inc. Combinacion de pdgf, kgf,igf e igfbp para curacion de heridas.
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6692961B1 (en) * 1996-10-11 2004-02-17 Invitrogen Corporation Defined systems for epithelial cell culture and use thereof
AU4751797A (en) * 1996-10-11 1998-05-11 Life Technologies, Inc. Defined systems for epithelial cell culture and use thereof
US6576659B1 (en) * 1996-12-05 2003-06-10 Bio-Technology General Corp. Use of oxandrolone in the treatment of burns an other wounds
US5866546A (en) * 1997-04-18 1999-02-02 Hadasit Medical Research Services And Development Company Ltd. Treatment for diabetes
US6129817A (en) * 1997-07-10 2000-10-10 Westvaco Corporation Unified on-line/off-line paper web formation analyzer
DE19821625C1 (de) * 1998-05-15 2000-01-05 Merck Patent Gmbh Pharmazeutische Zubereitung
GB9906715D0 (en) * 1999-03-23 1999-05-19 Ferring Bv Compositions for promoting growth
GB2362100B (en) 2000-05-08 2002-05-08 Maelor Pharmaceuticals Ltd Wound gels
KR100385293B1 (ko) * 2000-05-13 2003-05-23 주식회사 리젠 바이오텍 βｉｇ-ｈ3의 일부 도메인을 이용한 세포 부착 및 창상치유 방법
US7081240B1 (en) * 2000-06-28 2006-07-25 Zimmer Orthobiologics, Inc. Protein mixtures for wound healing
US20100129332A1 (en) * 2000-07-31 2010-05-27 Tamar Tennenbaum Methods and pharmaceutical compositions for healing wounds
US20030148924A1 (en) * 2002-07-09 2003-08-07 Tamar Tennenbaum Methods and pharmaceutical compositions of healing wounds
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
DE60138572D1 (de) * 2000-07-31 2009-06-10 Univ Bar Ilan Methoden und pharmazeutische zusammensetzungen zur wundheilung
GB2369572A (en) 2000-11-29 2002-06-05 Raft Trustees Ltd Wound treatment composition comprising insulin
US7115563B2 (en) * 2002-05-29 2006-10-03 Insignion Holding Limited Composition and its therapeutic use
GB0212405D0 (en) * 2002-05-29 2002-07-10 Insignion Holdings Ltd Composition and its therapeutic use
EP1635782A1 (de) * 2003-05-24 2006-03-22 JUVENA (International) AG Gewebekulturmedien als bestandteil von kosmetika
DK1651161T3 (da) 2003-08-07 2012-01-30 Healor Ltd Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
UA89781C2 (uk) * 2004-04-07 2010-03-10 Арес Трейдінг С.А. Рідкий склад гормона росту
US7312198B2 (en) * 2005-07-12 2007-12-25 Essential Skincare, Llc Protein compositions for promoting wound healing and skin regeneration
EP2452686A3 (de) 2005-08-29 2012-09-05 HealOr Ltd. Verfahren und Zusammensetzungen zur Vorbeugung und Behandlung von diabetischer und alternder Haut
US7718170B2 (en) * 2006-08-21 2010-05-18 Essential Skincare, Llc Alkaline phosphatase compositions to reduce skin cancer
US20080098491A1 (en) * 2006-10-19 2008-04-24 Zoltan Laboratories Llc Mouse models to study cachexia
FR2907683A1 (fr) * 2006-10-27 2008-05-02 De Potter Philippe Viseux Composition medicale pour cicatrisation des plaies et pansements permettant son application
CN101835486B (zh) * 2007-07-30 2012-12-12 希尔洛有限公司 用于治疗创伤的药物组合物以及相关方法
US20110045056A1 (en) 2008-01-17 2011-02-24 First Water Limited Hydrogel co-polymer composition and its uses, for example as a wound dressing
CN102325789A (zh) * 2009-02-24 2012-01-18 希尔洛有限公司 用于治疗痤疮和其它病症的内脂素治疗药物
GB0905290D0 (en) 2009-03-27 2009-05-13 First Water Ltd Multilayer compositions and dressings
EP2523677A2 (de) 2010-01-11 2012-11-21 Healor Ltd. Verfahren zur behandlung von entzündungskrankheiten und -erkrankungen
US9474685B2 (en) 2011-09-28 2016-10-25 Sure-Shot Medical Device Inc. Apparatus for localized dermatological treatment
WO2013187899A1 (en) * 2012-06-14 2013-12-19 Ella Lindenbaum Compositions and methods for stimulating wound healing
US11432990B2 (en) 2013-08-30 2022-09-06 ISOS Solutions, LLC Textured apparatus with therapeutic material incorporated therein and methods of manufacturing same
GB201318842D0 (en) 2013-10-24 2013-12-11 First Water Ltd Flexible hydrogel wound dressings
GB201713511D0 (en) 2017-08-23 2017-10-04 Scapa Uk Ltd Wound dressing
WO2020150548A1 (en) 2019-01-17 2020-07-23 Scapa Tapes Na Composition for use in wound dressings
IT201900022803A1 (it) * 2019-12-03 2021-06-03 Univ Degli Studi Di Ferrara Gel di alginato per la medicazione di ferite cutanee

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3904753A (en) * 1970-02-20 1975-09-09 Research Corp Clinically active bovine growth hormone fraction
US3664925A (en) * 1970-02-20 1972-05-23 Martin Sonenberg Clinically active bovine growth hormone fraction
US4342832A (en) * 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
HU195618B (en) * 1981-03-17 1988-06-28 Human Oltoanyagtermelo Process for producing composition for treating epidermic lesions of skin
US4863899A (en) * 1983-05-09 1989-09-05 Todaro George J Biologically active polypeptides
US4444760A (en) * 1983-06-17 1984-04-24 Merck & Co., Inc. Purification and characterization of a protein fibroblast growth factor
US4940666A (en) * 1983-07-15 1990-07-10 University Patents, Inc. Process and defined medium for growth of human epidermal keratinocyte cells
US4673649A (en) * 1983-07-15 1987-06-16 University Patents, Inc. Process and defined medium for growth of human epidermal keratinocyte cells
US5165938A (en) * 1984-11-29 1992-11-24 Regents Of The University Of Minnesota Wound healing agents derived from platelets
US4696917A (en) * 1985-08-01 1987-09-29 Lindstrom Richard L Irrigation solution
US4886786A (en) * 1985-08-01 1989-12-12 Lindstrom Richard L Additive for irrigation solution or surgical solution
NZ226170A (en) * 1987-09-18 1990-07-26 Ethicon Inc Stable freeze-dried pharmaceutical composition containing epidermal growth factor
US5034375A (en) * 1988-08-10 1991-07-23 Institute Of Molecular Biology, Inc. Process of wound healing using PDGF and EGF
GB8823649D0 (en) * 1988-10-07 1988-11-16 Geistlich Soehne Ag Chemical compounds
US5051443A (en) * 1988-10-12 1991-09-24 Eye Research Institute Of Retina Foundation, Inc. Method for enhancing healing of corneal endothelial wounds
US5036046A (en) * 1988-10-12 1991-07-30 Eye Research Institute Of Retina Foundation, Inc. Method for enhancing healing of corneal endothelial wounds
US5204325A (en) * 1988-12-15 1993-04-20 Lindstrom Richard L Viscoelastic solution
US5013714A (en) * 1988-12-15 1991-05-07 Lindstrom Richard L Viscoelastic solution
US5218093A (en) * 1989-03-01 1993-06-08 Allelix Biopharmaceuticals, Inc. EGF variants and pharmaceutical use thereof
US5219739A (en) * 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US5035887A (en) * 1989-09-07 1991-07-30 Institute Of Moelcular Biology, Inc. Wound healing composition of IL-1 and PDGF or IGF-1
US5056520A (en) * 1989-10-11 1991-10-15 Medex, Inc. Probe for blood gas sensing
EP0516901A1 (de) * 1991-06-06 1992-12-09 Richard L. Lindstrom Methode und Einrichtung für serumlose medizinische Lösung

Also Published As

Publication number Publication date
AU2587992A (en) 1993-04-05
FI940932L (fi) 1994-02-28
HUT67319A (en) 1995-03-28
HU9400593D0 (en) 1994-05-30
AU670413B2 (en) 1996-07-18
EP0650366B1 (de) 1999-11-24
US5461030A (en) 1995-10-24
WO1993004691A1 (en) 1993-03-18
DE69230344T2 (de) 2000-04-13
BR9206433A (pt) 1994-09-27
CA2116549A1 (en) 1993-03-18
EP0650366A4 (de) 1994-12-20
FI940932A7 (fi) 1994-02-28
JPH06510453A (ja) 1994-11-24
EP0650366A1 (de) 1995-05-03
DE69230344D1 (de) 1999-12-30
FI940932A0 (fi) 1994-02-28
IL101229A0 (en) 1992-11-15

Similar Documents

Publication Publication Date Title
DE69230344D1 (de) Zusammensetzungen und methoden zur wundbehandlung
DE69231486D1 (de) Zusammensetzung enthaltend pdgf und dexamethason zur förderung von gewebsreparatur und -regenerierung
DE69429450D1 (de) Die verwendung von angiotensin iii und seiner analoge für die gewebeheilung
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
NZ227788A (en) Peptide having growth hormone regulatory effects, and compositions
ATE188383T1 (de) Mischungen zum schutz und regenierung von geweben
DE69535264D1 (de) Verfahren zur behandlung von diabetes mittels kgf
EP0190018A3 (en) Use of transforming growth factor to promote wound healing and composition therefor
ATE435030T1 (de) Heilung von wunden oder fibrotischen krankheiten unter verwendung von wenigstens einem agens gegen einen wachstumsfaktor
ATE55695T1 (de) Verwendung von defibrotid zur herstellung pharmazeutischer zusammensetzungen zur behandlung peripherer arteriopathien.
DE69316013D1 (de) Verwendung von phosphinate zur behandlung der osteoporose
DE69018799D1 (de) IGF-I zur Behandlung von Nebeneffekten der Steroidtherapie.
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран
ATE53302T1 (de) Mittel zur behandlung von wunden.
ATE321045T1 (de) Methoden und zusammensetzungen zur behandlung von schmerzen
ATE178206T1 (de) Verfahren zur vorbeugung und behandlung von durch chemotherapie ausgelöster alopezie
ATE291918T1 (de) Kombinationstherapie zur behandlung von tumoren
ATE275580T1 (de) Verfahren zur induktion der herstellung von wachstumsfaktoren
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
ATE221310T1 (de) Neues verfahren zur kryokonservierung von pflanzen
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
ATE209042T1 (de) Verwendung des wachstumshormons in mitteln zur behandlung der insulinresistenz im herzen
NO940406L (no) Preparat og fremgangsmåte for behandling av sårskader
ATE178336T1 (de) Verwendung einer therapeutischen zusammensetzung zur behandlung von bronchitis
ATE163344T1 (de) Zusammensetzungen zur behandlung von geernteter pflanzenmaterial

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties